Literature DB >> 9124376

Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice.

S H Gavett1, D J O'Hearn, C L Karp, E A Patel, B H Schofield, F D Finkelman, M Wills-Karp.   

Abstract

The functional role of interleukin (IL)-4 in the development of airway hyperresponsiveness (AHR) and pulmonary eosinophilia in response to sensitization and challenge of mice with sheep red blood cells (SRBC) was examined. Control- and SRBC-sensitized A/J mice were treated with an antibody to the murine IL-4 receptor (anti-IL-4R) 3 days before intratracheal challenge with the antigen or vehicle only. Blockade of IL-4R significantly reduced antigen-induced AHR and prevented increases in goblet cells and bronchoalveolar lavage (BAL) eosinophils. Treatment with anti-IL-4R did not affect antigen-induced increases in lung mRNA and BAL protein levels of IL-5 and interferon-gamma or IL-4 mRNA but did significantly increase IL-4 protein levels. Antigen-induced AHR was not reduced by treatment with antibodies to the adhesion molecules, vascular cell adhesion molecule-1 and very late activation antigen-4. Administration of IL-4 over a 7-day period did not increase airway reactivity or induce any changes in BAL cell numbers in naive mice. These results demonstrate that IL-4 is necessary for in vivo development of antigen-induced AHR, goblet cell metaplasia, and pulmonary eosinophilia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9124376     DOI: 10.1152/ajplung.1997.272.2.L253

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  40 in total

Review 1.  Cytokine and anti-cytokine therapy for asthma.

Authors:  Hans-Uwe Simon
Journal:  Curr Allergy Asthma Rep       Date:  2006-03       Impact factor: 4.806

2.  Effect of a CD4-depleting antibody on the development of Cryptococcus neoformans-induced allergic bronchopulmonary mycosis in mice.

Authors:  Shikha Arora; Roderick A McDonald; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 3.  Usefulness and optimization of mouse models of allergic airway disease.

Authors:  Fred D Finkelman; Marsha Wills-Karp
Journal:  J Allergy Clin Immunol       Date:  2008-03       Impact factor: 10.793

Review 4.  Importance of cytokines in murine allergic airway disease and human asthma.

Authors:  Fred D Finkelman; Simon P Hogan; Gurjit K Khurana Hershey; Marc E Rothenberg; Marsha Wills-Karp
Journal:  J Immunol       Date:  2010-02-15       Impact factor: 5.422

Review 5.  Targeting key proximal drivers of type 2 inflammation in disease.

Authors:  Namita A Gandhi; Brandy L Bennett; Neil M H Graham; Gianluca Pirozzi; Neil Stahl; George D Yancopoulos
Journal:  Nat Rev Drug Discov       Date:  2015-10-16       Impact factor: 84.694

Review 6.  Asthma therapy and its effect on airway remodelling.

Authors:  Rachid Berair; Christopher E Brightling
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

7.  CCR2 and CCR6, but not endothelial selectins, mediate the accumulation of immature dendritic cells within the lungs of mice in response to particulate antigen.

Authors:  John J Osterholzer; Theresa Ames; Timothy Polak; Joanne Sonstein; Bethany B Moore; Stephen W Chensue; Galen B Toews; Jeffrey L Curtis
Journal:  J Immunol       Date:  2005-07-15       Impact factor: 5.422

8.  Seeking common pathophysiology in asthma, atopy and sinusitis.

Authors:  Paul C Porter; Valentine Ongeri; Amber Luong; Farrah Kheradmand; David B Corry
Journal:  Trends Immunol       Date:  2011-01-14       Impact factor: 16.687

Review 9.  Cytokine/anti-cytokine therapy - novel treatments for asthma?

Authors:  Philip M Hansbro; Gerard E Kaiko; Paul S Foster
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 10.  Aligning mouse models of asthma to human endotypes of disease.

Authors:  Rebecca A Martin; Samantha R Hodgkins; Anne E Dixon; Matthew E Poynter
Journal:  Respirology       Date:  2014-05-09       Impact factor: 6.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.